Diabetes Drug Adherence Examined Among Cancer Patients with T2DM

Patients who adhered to their oral antidiabetic Tx had 24% less all-cause hospitalization
Patients who adhered to their oral antidiabetic Tx had 24% less all-cause hospitalization

Among patients with cancer, researchers found a high prevalence of non-adherence to oral antidiabetic medications and negative consequences tied with non-adherence. Findings from the study are published in the Journal of Clinical Pharmacy and Therapeutics

Researchers conducted a retrospective study to assess oral antidiabetic drug use and related health outcomes in non-elderly American adults with cancer. They analyzed the Marketscan Commercial Claims and Encounters database from 2008–2009. Patients with concomitant diagnoses type 2 diabetes and breast, prostate, colon or lung cancer who were treated with oral antidiabetics were included. Medication adherence was measured using the Medication Possession Ratio (MPR); logistic regression was used to assess factors linked with non-adherence. 

Related Articles

Of the total 1,918 diabetic, cancer patients who were initiated on oral antidiabetics, only 37.6% were adherent. Likewise, a similar proportion of adherence was found in the non-cancer control population (35.8%; P=0.24). Factors such as younger age, living in the southern region, using combination therapy vs. monotherapy, and using retail vs. mail order pharmacy were significantly associated with non-adherence in patients with cancer. 

Adherence to oral antidiabetics was associated with 24% less all-cause hospitalization (P=0.02), the authors added. Overall, study findings highlight the importance of developing intervention strategies to improve diabetes management and treatment outcomes among diabetic cancer patients.

For more information visit onlinelibrary.wiley.com.

Loading links....